AI powers deep genomics gains as Pacific Biosciences of California improves sequencing accuracy and reduces costs

AI powers deep genomics gains as Pacific Biosciences of California improves sequencing accuracy and reduces costs
Pacific Biosciences cuts genome costs

Pacific Biosciences of California has announced a significant reduction in human genome sequencing costs, now down to approximately 345 dollars per genome. The company attributes this breakthrough to the integration of its SPRQ-Nx platform with advanced AI-driven analysis, as well as enhancements in DeepConsensus software in collaboration with AlphaEvolve.

The improvements reportedly also deliver higher accuracy in PacBio HiFi reads, accelerating progress in genomics and broadening access to affordable, high-fidelity genomic data. This move may facilitate further advances in personalized medicine and large-scale genomic research.

Earlier this year, Pacific Biosciences launched a HiFi sequencing workshop at AACR26 focused on cancer genomics and epigenomics research. The company also reported that PacBio HiFi whole genome sequencing improved detection of disease-linked structural variants across diverse populations in a recent advance in disease research. These initiatives add context to the firm's drive for lower costs and higher accuracy in genome sequencing.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.